Haemonetics Corporation‘s (NYSE: HAE) shares have increased 10.8% year to date compared with the industry's rise of 6.1%. The Medical sector has gained 1% in the said time frame. The company has a market capitalization of $4.82 billion. The consistent growth performance in the past few quarters, reflecting its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns, is likely to drive this Zacks Rank 1 (Strong Buy) stock. Its earnings are expected to grow 12% in the next five years. HAE's ROE for the trailing 12 months was 4.6%, better than the industry average of 0.2%. Will the Upside Continue? The Zacks Consensus Estimate for HAE's 2025 earnings is pegged at $1.40, indicating a 6.9% increase from the year-ago reported figure. The consensus estimate for 2025 revenues is pegged at $4.46 billion, indicating a year-over-year improvement of 12.6%. Haemonetics is gaining from the newly-completed limited market release of the new Express Plus technology with more than 60,000 real-world collections. Haemonetics is currently initiating its full-market release in the United States. This technology is fast gaining new customers. The rollout of Persona — the company's proprietary technology proven to increase yield from 9% to 12% on average — continues to gain momentum, with more than 25 million collections. During the fiscal fourth-quarter update, management noted that the continued transition from the company's PCS2 devices to the latest NexSys with Persona Technology ...